Year: 2016

Opsona News 2

Preliminary results in Opsona’s myelodysplastic syndrome study

Dublin, Ireland – Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announces the preliminary results from its ongoing prospective, open label Phase I/II study being conducted with OPN-305 in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) which …

Preliminary results in Opsona’s myelodysplastic syndrome study Read More »

Labcyte News Logo

Labcyte Announces Collaboration with Notable Labs

Sunnyvale, CA, and San Francisco, CA. 7 December 2016.  Labcyte Inc. and Notable Labs today announced a collaboration to apply the unique capabilities of Labcyte’s revolutionary Echo® acoustic liquid handling technology to screen individual cancer patients’ tumor cells.  This functional screening identifies which available drugs or drug combinations may be most effective at treating their …

Labcyte Announces Collaboration with Notable Labs Read More »

Opsona News

Opsona presents preliminary results at 58th Annual ASH Meeting

Seroba’s investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it will present preliminary results from its ongoing prospective, open label Phase I/II study being conducted with OPN-305 in second-line lower (Low and intermediate-1) risk myelodysplastic …

Opsona presents preliminary results at 58th Annual ASH Meeting Read More »

Opsona News 3

Opsona receives orphan designation for MDS with OPN-305.

Seroba’s investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it has received orphan drug designation (ODD) from United States Food and Drug Administration for myelodysplastic syndromes (MDS). Myelodysplastic syndromes are a complex and heterogeneous …

Opsona receives orphan designation for MDS with OPN-305. Read More »

Veryan Premarket Approval

Veryan Completes enrolment into the MIMICS-2 clinical study

The MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of BioMimics 3D in the treatment of patients with symptomatic femoropopliteal disease. The Study is being conducted under a USA Food and Drug Administration (FDA) Investigational Device Exemption (IDE), with Japanese Pharmaceuticals and Medical Devices Agency (PMDA) concurrence under …

Veryan Completes enrolment into the MIMICS-2 clinical study Read More »

Quanta News

Quanta presents interim analysis of first 255 treatments using SC+

Seroba’s investee company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announced that it will present a poster at a moderated session on Friday 23rd September at 11:30am-12:30pm at the 10th International Congress of the International Society of Haemodialysis (ISHD). …

Quanta presents interim analysis of first 255 treatments using SC+ Read More »

Veryan Premarket Approval

Veryan announces first patient enrolment into MIMICS-3D Registry

MIMICS-3D is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Self-Expanding Stent System in the treatment of peripheral arterial disease. The Registry will evaluate safety, effectiveness and device performance within a real-world clinical population in a minimum of 500 patients across Europe. The MIMICS-3D Registry PI, Michael Lichtenberg MD (Arnsberg, Germany) commented: “Having …

Veryan announces first patient enrolment into MIMICS-3D Registry Read More »

T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top